胃癌、结直肠癌患者血清瘦素和脂联素变化及相关性分析

Changes and correlation analysis of serum leptin and adiponectin expression in patients with gastric and colorectal cancer

目的明确胃癌和结直肠癌患者血清瘦素、脂联素表达水平变化及其与发病的相关性。方法连续纳入2015年4月1日至2016年1月31日期间胃癌患者53例,结直肠癌患者48例,非肿瘤对照组患者56例,检测血清瘦素和脂联素表达水平,比较胃癌、结直肠癌组与非肿瘤对照组的血清瘦素和脂联素的表达变化,并进行相对危险度及相关性分析。结果对人口学特征及疾病特征比较后发现,三组患者在性别(χ2=27.353,P=0.000)、年龄(χ2=9.953,P=0.007)、受教育程度(χ2=27.527,P=0.000)及肿瘤家族史(χ2=133.503,P=0.000)方面存在差异。与非肿瘤对照组比较,胃癌组患者血清瘦素表达水平升高[(6.02±1.83)vs(4.76±1.62),P=0.013]、结直肠癌组患者血清瘦素表达水平升高[(6.21±1.74)vs(4.76±1.62),P=0.006];胃癌组患者血清脂联素表达水平降低[(4.43±0.48)vs(4.90±0.39),P=0.000]、结直肠癌组患者血清脂联素表达水平降低[(4.41±0.42)vs(4.90±0.39),P=0.000]。按病理分型对数据进行分层比较,高、中、低分化三组间无统计学差异。按肿瘤不同分期进行分层比较,早期与中晚期肿瘤两组数据间无统计学差异。将胃癌、结直肠癌组与非肿瘤对照组患者血清瘦素、脂联素水平按照四分位数分层后,进行相对危险度分析,胃癌、结直肠癌组血清瘦素风险比值分别为3.51和9.23,血清脂联素OR值分别为0.20和0.07。结论血清瘦素水平升高是胃癌、结直肠癌发病的风险因素,血清脂联素水平是胃癌、结直肠癌发病的保护因素,血清脂联素水平的降低增加了胃癌、结直肠癌的发病风险。血清瘦素、脂联素水平变化可能与胃癌、结直肠癌的发病相关。

Objective To determine the changes of serum leptin and adiponectin levels in patients with gastric cancer and colorectal cancer and their correlation with pathogenesis.Methods A total of 53 patients with gastric cancer,48 patients with colorectal cancer,and 56 patients with non-tumor control were enrolled in the period from April 1,2015 to January 31,2016.Serum leptin and adiponectin were detected.Serum leptin and adiponectin expression in gastric cancer,colorectal cancer and non-tumor control groups were compared,and relative risk and correlation analysis were performed.Result After comparing the demographic characteristics and disease characteristics,the three groups of patients were found that have significant difference in gender(χ2=27.353,P=0.000),age(χ2=9.953,P=0.007),and education level(χ2=27.527,P=0.000),the family history of the tumor(χ2=133.503,P=0.000).Compared with the non-tumor control group,the serum leptin expression level was increased in the gastric cancer group[(6.02±1.83)vs(4.76±1.62),P=0.013],and the serum leptin expression level was increased in the colorectal cancer group[(6.21±1.74)vs(4.76±1.62),P=0.006];serum adiponectin expression decreased in patients with gastric cancer[(4.43±0.48)vs(4.90±0.39),P=0.000],and serum adiponectin expression decreased in patients with colorectal cancer[(4.41±0.42)vs(4.90±0.39),P=0.000].The data were stratified by pathological classification,and there was no statistical difference between the three groups of high,medium and low differentiation.There were no statistical differences between the two groups in the early and middle-stage tumors.The serum leptin levels and adiponectin levels in the gastric cancer,colorectal cancer and non-tumor control groups were stratified by quartiles,and the relative risk analysis was performed.The serum leptin odds ratio(OR)of gastric cancer and colorectal cancer group OR values were 3.51 and 9.23,and the serum adiponectin OR values were 0.20 and 0.07.Conclusion Elevated serum leptin level is a risk factor for gastric cancer and colorectal cancer.Serum adiponectin level is a protective factor for gastric cancer and colorectal cancer,but the decrease of serum adiponectin level will increases gastric cancer and colorectal cancer's risk of onset.Changes in serum leptin and adiponectin levels may be associated with the pathogenesis of gastric cancer and colorectal cancer.